// App-Quantinova.ai

: Baseline Suvmax Did Not Predict Histological Transformation from Follicular Lymphoma to Aggressive Lymphoma in the Phase III GALLIUM Study

Researchers

Presenter

  • Farheen Mir

Principal Investigators

  • Sally F Barrington

  • Michel Meignan

  • Helen Brown

  • Tina Nielsen

  • Deniz Sahin

  • Judith Trotman

Medical Centers

  • King’s College London and Guys’& St Thomas PET Imaging Centre, School of Biomedical Engineering and Imaging Sciences, King’s College London, London, United...

  • Hôpital Henri Mondor and Université Paris-Est Créteil, Paris, France

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Concord Repatriation General Hospital, University of Sydney, Sydney, Australia

Locations

  • United Kingdom

  • France

  • Switzerland

  • Australia

Companies

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Follicular lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Fludeoxyglucose (18F)

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01332968

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved